Trial Profile
Phase 2b study of the safety, efficacy and pharmacokinetics of telaprevir in combination with peginterferon alpha 2a + ribavirin in liver transplant patients with recurrent hepatitis C genotype 1 (REFRESH)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms REFRESH
- Sponsors Vertex Pharmaceuticals
- 16 May 2013 Interim data, from the first 23 patients, presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
- 16 May 2013 New trial record